Matthew Winton's most recent trade in Inozyme Pharma Inc was a trade of 14,355 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 0.74 per share. | 25 Jun 2025 | 14,355 | 21,743 | - | 0.7 | 10,623 | Common Stock |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 0.77 per share. | 31 Mar 2025 | 2,490 | 7,388 | - | 0.8 | 1,917 | Common Stock |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 41,500 | 41,500 | - | - | Restricted Stock Units | |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 4.45 per share. | 30 Sep 2024 | 1,710 | 4,898 | - | 4.5 | 7,610 | Common Stock |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 3.33 per share. | 28 Mar 2024 | 3,188 | 3,188 | - | 3.3 | 10,616 | Common Stock |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Matthew Winton | COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 250,000 | 250,000 | - | - | Stock option (right to buy) |